INS and type 2 diabetes mellitus: Indeed, numerous studies suggest that glucose‐lowering agents may have beneficial (i.e., metformin and meglitinides) or undesirable (such as insulin) effects on COVID‐related mortality, albeit the conclusions are confounding and should be interpreted with caution, in view of the syndromic nature of COVID comorbidities, such as type 2 diabetes, as well as the use of different medications at distinct disease stages [40, 55, 56].